Observation the combined therapeutic efficacy and safety of Ganshulin 3OR and sitagliptin for elderly patients with DM2

Objective: To explore Ganshulin 30R and sitagliptin combined therapy for eldery patients with type 2 diabetes control over glucose stability and the safety of medication. Methods: select 21 cases of single Ganshulin 30R treatment with poor glucose control of elderly patient with DM2, after combined treatment with sitagliptin followed the immune biochemical methods for glucose HbAlc as well as kidney and liver function indices(ALT, UMAL)for dynamic observation, also to compare the levels before combined therapy. Results: A comparison between the results before combined therapy of fasting and 2 hr after meal. Blood glucose level showed (9.9 ± 1.71 mmol/L) and (11.8 ± 2.35 mmol/L), after 4 wk of combined therapy, blood glucose reduced to (8.2 ± 1.51 mmol/L) and (10.0 ± 1.74 mmol/L), average dropped by (1.7 mmol/L) and (1.8 mmol/L), with significant difference. After 8-12 wk of combined therapy fasting and postgrandial 2 h, glucose level remained on.(7.4 ± 1.75 mmol/L-6.7 ± 1.05 mmol/L) and (9.1 ± 1.38 mmol/L-8.5 ± 1.21 mmol/L) distinctly, there were no statistically significant difference (P < 0.05). After 12 wk of combined therapy, the glycosylated hemoglobin level significantly lower than before treatment (P < 0.01), dose of Gangshulin much less prominently, comparison with before treatment, the difference showed no significant difference (P > 0.05). Whether before or after treatment indexes of liver and kidney function (ALT, Cr)expressed no more difference significantly. Conclusion: Ganshulin 30R and oral sitagliptin medications combined therapy might be of good control and to stabilize elderly patients with DM2 on blood glucose level, also could reduce the dose of Ganshulin and provides safety. (authors)